PerkinElmer Showcases Expanded Reagent, Imaging, and Detection System Offerings for Advancing Research and Discovery at the Society for Neuroscience Conference

PerkinElmer, Inc has announced the introduction of several new tools to improve the speed and effectiveness of research for neurological disorders such as Alzheimer's, Parkinson's, multiple sclerosis and other central nervous system disorders.

"PerkinElmer continues its tradition of being an integral part of the Society for Neuroscience annual meeting," said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer. "This year we are introducing several new tools to study cellular signaling, including cellular and biochemical assays, 3D live cell imaging, innovative data management software, and a new ultra sensitive luminescent plate reader. All of these tools are focused to enable researchers to improve the speed and efficiency of their research."

He added, "At Neuroscience we are also sharing information on the integration of the recently purchased intangible assets from GE Healthcare, including the 3H & 14C catalog radiochemicals, SPA Reagents and CytoStar-TTM microplate products. These assets complement and strengthen our research reagent solutions, furthering our customers' important medical and drug development research, while also demonstrating our continuing leadership position in radiochemicals."